Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085887 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
A Phase 1 study of Brain Tumor, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04085887: Recruiting Phase 1 study of Brain Tumor, sponsored by Stanford University.
NCT04085887 is a Phase 1 study of Brain Tumor that is actively recruiting participants, run by Stanford University. The registered enrollment target is 12 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04085887, a Phase 1 study of Brain Tumor, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Primary Outcome
Adverse events related to the agent or procedure are considered toxicities, and is assessed as the number of Grade 2 or higher adverse events which have been determined to be clinically-significant and definitely, probably, or possibly-related to the study treatment or procedure. The outcome is reported by dose treatment group (cohort) as a number without dispersion.
Conditions Studied
Interventions
- DRUG Panitumumab-IRDye800
- DEVICE Pinpoint-IR9000 endoscopic/handheld device
- DEVICE Explorer Air camera
- DEVICE PDE-NEO-II
Study Locations (1)
California
- Stanford Cancer Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT04085887 shows while recruiting
NCT04085887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 4 interventions - of which Panitumumab-IRDye800 is the first listed.
NCT04085887 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04085887 about?
NCT04085887 is a clinical study titled "Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures". The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
What is the current status of trial NCT04085887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-04. Estimated completion is 2028-12.
What conditions does trial NCT04085887 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT04085887?
The interventions under investigation include: Panitumumab-IRDye800 (DRUG), Pinpoint-IR9000 endoscopic/handheld device (DEVICE), Explorer Air camera (DEVICE), PDE-NEO-II (DEVICE).
Who is sponsoring clinical trial NCT04085887?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085887 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04085887's enrollment target sits among peer trials
12 62nd of 69 higher than 8 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia